CN1277031A - 抗银屑病胶囊及其制备方法 - Google Patents
抗银屑病胶囊及其制备方法 Download PDFInfo
- Publication number
- CN1277031A CN1277031A CN 00105176 CN00105176A CN1277031A CN 1277031 A CN1277031 A CN 1277031A CN 00105176 CN00105176 CN 00105176 CN 00105176 A CN00105176 A CN 00105176A CN 1277031 A CN1277031 A CN 1277031A
- Authority
- CN
- China
- Prior art keywords
- radix
- ethanol
- precipitation
- add
- glycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims description 19
- 201000004681 Psoriasis Diseases 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 11
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 4
- 229940010454 licorice Drugs 0.000 claims abstract description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 96
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 235000019441 ethanol Nutrition 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 27
- 238000001556 precipitation Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 150000002338 glycosides Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 15
- 229930182482 anthraquinone glycoside Natural products 0.000 claims description 15
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 15
- 229960003321 baicalin Drugs 0.000 claims description 15
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 claims description 14
- 239000004378 Glycyrrhizin Substances 0.000 claims description 14
- 241001071917 Lithospermum Species 0.000 claims description 14
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 claims description 14
- 229940098421 anthraquinone glycoside Drugs 0.000 claims description 14
- 150000008139 anthraquinone glycosides Chemical class 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 14
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 14
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 14
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 14
- 238000012546 transfer Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 238000009413 insulation Methods 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 4
- 108010076723 adducin Proteins 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 244000061458 Solanum melongena Species 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229910000474 mercury oxide Inorganic materials 0.000 claims description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 238000000605 extraction Methods 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 3
- NEZONWMXZKDMKF-UHFFFAOYSA-N C.I. Natural Red 20 Chemical compound C1=CC(O)=C2C(=O)C(C(O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-UHFFFAOYSA-N 0.000 abstract 1
- 235000011030 Lithospermum officinale Nutrition 0.000 abstract 1
- 240000004035 Lithospermum officinale Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000000073 effect on psoriasis Effects 0.000 abstract 1
- 229940100691 oral capsule Drugs 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 150000004056 anthraquinones Chemical class 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010061372 Streptococcal infection Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940046892 lead acetate Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JGQGCJKPBAYEHO-UHFFFAOYSA-N 1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]ethyl]piperazine-2,6-dione Chemical compound C1C(=O)N(CN2CCOCC2)C(=O)CN1CCN(CC1=O)CC(=O)N1CN1CCOCC1 JGQGCJKPBAYEHO-UHFFFAOYSA-N 0.000 description 2
- GBLIGNUYGOFIKS-UHFFFAOYSA-N 4-[2-(3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione Chemical compound C1C(=O)NC(=O)CN1CCN1CC(=O)NC(=O)C1 GBLIGNUYGOFIKS-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229930185278 anthraglycoside Natural products 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- OOMYACICIIMLQI-UHFFFAOYSA-L lead(2+);diacetate;hydrate Chemical compound O.[Pb+2].CC([O-])=O.CC([O-])=O OOMYACICIIMLQI-UHFFFAOYSA-L 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- LUIGNPZNIFQHGQ-UHFFFAOYSA-L magnesium methanol diacetate Chemical compound CO.C(C)(=O)[O-].[Mg+2].C(C)(=O)[O-] LUIGNPZNIFQHGQ-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种抗银屑病胶囊及其制备方法,该胶囊是由黄芩、大黄、虎杖、紫草、甘草五味中药为原料,经提取有效成分制备而成的口服胶囊剂。该药用药安全可靠,疗程短,治愈率高,没有任何毒副作用。对寻常型、脓胞型、红皮症型、关节型银屑病都有显著的疗效。无论患病时间长短,一般口服胶囊30天即可见效。同时对高血脂、甘油三酯都有降低作用,能保护心脑血管。制备本品药源易得,提取工艺易掌握,可工业化生产。
Description
本发明涉及一种抗银屑病胶囊及其制备方法。
银屑病是常见的一种皮肤病,中医认为风邪、湿邪、血热而引起的。现代医学认为是链球菌感染,免疫功能障碍等有关。目前,国内外对银屑病多采用药物治疗,但仍存在以下棘手问题:
(1)、西药乙双吗啉、乙亚胺、白血宁都有一定疗效。但乙双吗啉副作用太大,病人服用后死亡率较高,现已停用;而乙亚胺、白血宁对血液、骨骼都造成破坏作用。
(2)、肾上腺皮质激素类药物能控制银屑病,但有反弹作用,使病情更加严重,造成对其它中西药都没有疗效,对肾脏有副作用。
(3)、服中药、成药疗效不稳定,有的成药含汞性成分,对肝、肾都有毒性作用。
本发明的目的就在于解决以上药物治疗银屑病的棘手问题,提供一种具有祛风祛湿,清热解毒,对链球菌感染,病毒感染,免疫功能障碍等都有显著疗效的中成药。该药用药安全可靠,疗程短,治愈率高,没有任何毒副作用。
本发明抗银屑病胶囊,是由黄芩、大黄、虎杖、紫草、甘草五味中药为原料,经提取有效成分制备而成,按每粒胶囊剂量计,各组分及含量为:
黄芩甙及甙元0.01~0.39g
大黄蒽醌甙及甘草皂甙混合物0.01~0.39g
紫草素0.01~0.05g
虎杖提取物0.01~0.05g
其制备方法的工艺步骤为:
(1)、药物提取
a、黄芩取3年植株,春季采集,上锅蒸10min取出,去皮晒干制成饮片,用pH7-8石灰水煎煮三次,每次煎煮时间(1.5h,1h,0.5h),煎液过滤,浓缩,用稀盐酸调pH1-2,保温在75℃-85℃,30min,弃上清液,取沉淀,用蒸馏水调成糊状,用40%氢氧化钠溶液调pH7,然后加入与药液量相等的95%乙醇,水浴加温到45℃-60℃,加入10%稀盐酸调pH1-2,保温35~45min,虹吸上清液,取沉淀,用95%乙醇洗至无红色洗出,50℃-60℃干燥即得黄芩甙及甙元;
b、取存放二年以上大黄饮片及甘草饮片按1∶0.5的比例打成20目粗粉,用75%乙醇湿润,装入渗漏桶中,加入生药3倍量的70%乙醇,浸24h,开始渗漏,每分钟45滴,渗漏液过滤,加入生药量3%氯化钙水溶液,搅拌5min,然后用50%氢氧化钠溶液,调pH8,开始发生沉淀,沉淀放置一周,虹吸上清液,取沉淀用85%乙醇洗涤,然后60℃干燥得大黄蒽醌甙及甘草皂甙混合物;
c、取紫草饮片粗粉,加入95%乙醇,在30℃温度下浸三次,每次48h,合并浸滤液,回收乙醇得浸膏,加适量蒸馏水,用20%氢氧化钠溶液调成紫色变为蓝色为止,过滤滤液再加入稀盐酸,析出紫红色沉淀为止,取沉淀用蒸馏水洗至中性,50℃-60℃以下干燥得紫草素;
d、取虎杖饮片打成粗粉,用95%乙醇在30℃温度下浸泡三次,每次48h,合并三次滤液,回收乙醇得流浸膏,加入适量蒸馏水,用氯仿回流,回收氯仿层和水层,氯仿层冷藏析出黄色沉淀,水层加入乙酸乙酯放置析出棕红色沉淀,然后取两种沉淀用乙醇重结晶,即得虎杖提取物;
(2)、制备
取0.01~0.39g黄芩甙及甙元、0.01~0.39g大黄蒽醌甙及甘草皂甙混合物、0.01~0.05g紫草素及0.01~0.05g虎杖提取物,混合制成80目药粉,按每粒胶囊0.1~0.5g,紫外线照射下装入胶囊即可。
本发明选用天然植物药为原料,其中:
黄芩,含黄芩甙及甙元,药理作用有抗炎、抗菌、抗病毒作用,能抑制链球菌感染。其中甙元是治疗银屑病最有效的成分,为了提高疗效,本发明对原有的提取工艺进行改革,按照黄芩的性质,能溶于碱性水溶液,所以用石灰水作溶媒提取甙及甙元有效成分,用石灰水作溶媒特别对甙元提取起到决定性作用。
大黄,含大黄蒽醌甙类,还含有多种微量元素。药理作用有广普抗菌作用,抗病毒作用,能激发机体产生干扰素,提高抗病能力,减轻血中内毒素。其中游离蒽醌是主要的抑菌成分,临床证明还有降低高血脂症,尤其降低甘油三脂与高β-脂蛋。因大黄分子中含α-羟基或二个邻位羟基能与Pb++、Al++、Mg++等生成络合物在水溶液中溶解度比较低的性质,所以老工艺加入醋酸铅水溶液来提取蒽醌甙类有效成分。本发明改革了老工艺用醋酸铅,现工艺用没有毒的氯化钙CaCl2代替有毒的醋酸铅。因提取甘草皂甙的工艺和大黄工艺一样,所以加到一起提取,据报道两种药在一起提可能产生新的物质提高疗效。同时甘草成分具有促进肾上腺皮质激素样作用,用乙醇作溶媒能够提取有效的游离蒽醌及蒽甙类成分。
紫草、虎杖都含蒽醌类物质,按化学性质,用不同提取办法进行。药理作用两种物质都有抗病毒、抗菌、抗炎作用,对银屑病进行期病变疗效较好。
本发明药物成分的定性鉴别反应如下:
(1)黄芩甙用蒸馏水5ml溶解,加入醋酸铅试液3-6滴,产生橘红色的沉淀,含黄芩甙及甙元。
(2)取混合提取物用乙醇溶解,滴于硅胶板上用展开剂——甲苯∶二氯甲烷∶冰醋酸(6∶3∶1)混合液展开,芦荟大黄素RF值0.22-0.26,大黄素RF值0.28-0.31,大黄酸RF值0.34-0.37,大黄酸>0.9RF值,大黄甲醚>0.9RF值,含大黄蒽醌甙类。
(3)紫草素,取紫草素溶于乙醇中,取5ml加入2%氢氧化钠NaOH溶液1.5ml,溶液由紫红色变为蓝色,含紫草素。
(4)取虎杖提取物溶于乙醇中,取5ml加入0.5%醋酸镁甲醇试液1ml,可显橙、红、蓝色或紫色络合物,含大黄素。
(5)取大黄蒽醌甙及甘草皂甙混合物,用蒸馏水溶解作溶血反应,溶血指数1∶4000。也可用溶解液装入试管烧开后大量气泡产生,含甘草皂甙。
本发明抗银屑病胶囊经临床使用结果表明有下述优点:
(1)、抗银屑病胶囊在临床上治疗寻常型银屑病、脓胞型银屑病、红皮症型银屑病、关节型银屑病都有显著的疗效。无论患病时间长短,一般口服抗银屑灵胶囊,成人每天2~4粒,儿童减半,30天即可见效。
(2)、本发明选用天然植物药为原料,通过科学配伍提取有效成分,提取新的物质,提高疗效。
(3)、本发明治疗功能是:活血化瘀、抗菌、抗炎、抗病毒,能增强机体免疫等。口服没有任何毒副作用,安全可靠,同时对高血脂、甘油三脂都有降低作用,能保护心脑血管。
(4)、原料不缺、成本不高,提取工艺易掌握,可工业化生产。
(5)、本胶囊剂口服方便吸收快,可掩盖药物不适的苦味及臭味。药物的生物利用度较片剂高,能提高药物的稳定性。弥补其它固体剂型的不足。
(6)、为表明本发明药物对银屑病的治疗效果,经180例临床观察。男性:年龄15-56(平均28±4、37岁)96人,女性年龄21-45(平均33±7、14岁)84人。病程1年-16年(平均3、7±6、6年)。寻常型90例、红皮症病型36例、关节病型36例、脓疱型18例。
治疗结果:临床痊愈108例,有效66例,无效6例。
观察指标:治愈,红斑丘疹消退,鳞屑消失,搔痒消失;有效,红斑丘疹缩小变淡,鳞屑减少,搔痒减轻,皮损消退50%以上;无效,红斑,丘疹无明显改变,鳞屑无明显减少,搔痒无缓解,皮损消退少于50%。该药抗银屑灵胶囊总有效率为95%以上。
下面以实施例加以说明。
实施例1
(1)、药物提取
a、黄芩甙及甙元的提取,取炮制过的黄芩粗粉100g,加6倍量pH7-8石灰水,煮沸1、5h用两层纱布过滤,药渣再加4倍量石灰水煮沸1h,过滤药渣再加3倍量的石灰水煮沸0.5h,过滤,合并三次煮沸提取液,加稀盐酸HCl调pH1-2,80℃保温30min,虹吸上清液,将沉淀物加上热蒸馏水调和成糊状,再加40%氢氧化钠NaOH溶液调节pH7使黄芩甙及甙元溶解,加入等体积95%乙醇,使溶液含醇量约为50%,加热至50℃抽滤得滤液,滤液用10%稀盐酸HCl调pH1-2,50℃保温30min,弃上清液,收集沉淀、抽滤,用95%乙醇洗涤,并抽干,60℃干燥后得黄芩甙及甙元,收率3%。
b、大黄蒽醌及甘草皂甙混合物的提取,取存放二年以上的大黄100g,甘草50g打成20目粗粉,用75%乙醇湿润,装入渗漏桶中,加入生药3倍量的70%乙醇,浸24h,开始渗漏,每分钟45滴。取渗漏液用三层纱布过滤,加入生药量3%氯化钙CaCl2溶液150ml,搅拌5min,然后用50%氢氧化钠NaOH溶液,调pH8,放置7天。虹吸上清液,抽滤沉淀用85%乙醇洗涤,然后60℃温度干燥得大黄蒽醌甙及甘草皂甙混合物,收率8%。
c、紫草素提取,取紫草饮片粗粉100g,加入3倍量95%乙醇,在30℃温度下浸三次,每次48h,合并三次浸液,三层纱布过滤,回收乙醇得浸膏,加入50ml蒸馏水,搅拌。用20%氢氧化钠NaOH溶液调成紫色变为蓝色为止,三层纱布过滤,滤液加入稀盐酸HCl析出沉淀,沉淀用蒸馏水洗至中性,60℃以下干燥得紫草素,收率1%。
d、虎杖提取物,取虎杖100g打成20目的粗粉,用3倍量95%乙醇,在30℃温度下浸三次,每次48h,合并浸液,纱布过滤回收乙醇得流浸膏,加入30ml蒸馏水,用10ml氯仿回流30min,回收氯仿层和水层,氯仿层放入冰箱冷藏12h,有黄色沉淀,回收氯仿,水层加入乙酸乙酯10ml,滤液放置析出棕红色沉淀,然后取两种沉淀,用95%乙醇溶解为止,抽滤,回收乙醇得虎杖提取物,收率5%。
(2)、制备
取0.01g黄芩甙及甙元、0.07g大黄蒽醌甙及甘草皂甙混合物、0.01g紫草素及0.01g虎杖提取物,混合制成80目药粉,紫外线照射下装入0.1g胶囊即可。
实施例2
(1)、药物提取同实施例1。
(2)、制备
取0.12g黄芩甙及甙元、0.12g大黄蒽醌甙及甘草皂甙混合物、0.03g紫草素及0.03g虎杖提取物,混合制成80目药粉,紫外线照射下装入0.3g胶囊即可。
实施例3
(1)、药物提取同实施例1。
(2)、制备
取0.2g黄芩甙及甙元、0.2g大黄蒽醌甙及甘草皂甙混合物、0.05g紫草素及0.05g虎杖提取物,混合制成80目药粉,紫外线照射下装入0.5g胶囊即可。
Claims (2)
1、一种抗银屑病胶囊,其特征在于该胶囊是由黄芩、大黄、虎杖、紫草、甘草五味中药为原料,经提取有效成分制备而成,按每粒胶囊剂量计,各组分及含量为:
黄芩甙及甙元0.01~0.39g
大黄蒽醌甙及甘草皂甙混合物0.01~0.39g
紫草素0.01~0.05g
虎杖提取物0.01~0.05g
2、一种抗银屑病胶囊的制备方法,其特征在于该制备方法的工艺步骤为:
(1)、药物提取
a、黄芩取3年植株,春季采集,上锅蒸10min取出,去皮晒干制成饮片,用pH7-8石灰水煎煮三次,每次煎煮时间(1.5h,1h,0.5h),煎液过滤,浓缩,用稀盐酸调pH1-2,保温在75℃-85℃,30min,弃上清液,取沉淀,用蒸馏水调成糊状,用40%氢氧化钠溶液调pH7,然后加入与药液量相等的95%乙醇,水浴加温到45℃-60℃,加入10%稀盐酸调pH1-2,保温35~45min,虹吸上清液,取沉淀,用95%乙醇洗至无红色洗出,50℃-60℃干燥即得黄芩甙及甙元;
b、取存放二年以上大黄饮片及甘草饮片按1∶0.5的比例打成20目粗粉,用75%乙醇湿润,装入渗漏桶中,加入生药3倍量的70%乙醇,浸24h,开始渗漏,每分钟45滴,渗漏液过滤,加入生药量3%氯化钙水溶液,搅拌5min,然后用50%氢氧化钠溶液,调pH8,开始发生沉淀,沉淀放置一周,虹吸上清液,取沉淀用85%乙醇洗涤,然后60℃干燥得大黄蒽醌甙及甘草皂甙混合物;
c、取紫草饮片粗粉,加入95%乙醇,在30℃温度下浸三次,每次48h,合并浸滤液,回收乙醇得浸膏,加适量蒸馏水,用20%氢氧化钠溶液调成紫色变为蓝色为止,过滤滤液再加入稀盐酸,析出紫红色沉淀为止,取沉淀用蒸馏水洗至中性,50℃-60℃以下干燥得紫草素;
d、取虎杖饮片打成粗粉,用95%乙醇在30℃温度下浸泡三次,每次48h,合并三次滤液,回收乙醇得流浸膏,加入适量蒸馏水,用氯仿回流,回收氯仿层和水层,氯仿层冷藏析出黄色沉淀,水层加入乙酸乙酯放置析出棕红色沉淀,然后取两种沉淀用乙醇重结晶,即得虎杖提取物;
(2)、制备
取0.01~0.39g黄芩甙及甙元、0.01~0.39g大黄蒽醌甙及甘草皂甙混合物、0.01~0.05g紫草素及0.01~0.05g虎杖提取物,混合制成80目药粉,按每粒胶囊0.1~0.5g,紫外线照射下装入胶囊即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00105176A CN1090485C (zh) | 2000-04-15 | 2000-04-15 | 抗银屑病胶囊及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00105176A CN1090485C (zh) | 2000-04-15 | 2000-04-15 | 抗银屑病胶囊及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1277031A true CN1277031A (zh) | 2000-12-20 |
| CN1090485C CN1090485C (zh) | 2002-09-11 |
Family
ID=4577581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00105176A Expired - Fee Related CN1090485C (zh) | 2000-04-15 | 2000-04-15 | 抗银屑病胶囊及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1090485C (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063753A1 (zh) * | 2009-11-26 | 2011-06-03 | 桂林商源植物制品有限公司 | 用于治疗口腔溃疡、肿瘤的中药组合物及其制备方法和用途 |
| CN101049341B (zh) * | 2007-05-16 | 2011-11-09 | 长春同春堂皮肤病医院 | 一种治疗银屑病的中药制剂 |
| CN103373913A (zh) * | 2012-04-15 | 2013-10-30 | 四川省中医药科学院 | 紫草素的提取方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044091C (zh) * | 1993-09-07 | 1999-07-14 | 刘岐干 | 一种治疗银屑病的中药胶囊制剂 |
-
2000
- 2000-04-15 CN CN00105176A patent/CN1090485C/zh not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049341B (zh) * | 2007-05-16 | 2011-11-09 | 长春同春堂皮肤病医院 | 一种治疗银屑病的中药制剂 |
| WO2011063753A1 (zh) * | 2009-11-26 | 2011-06-03 | 桂林商源植物制品有限公司 | 用于治疗口腔溃疡、肿瘤的中药组合物及其制备方法和用途 |
| CN102724991A (zh) * | 2009-11-26 | 2012-10-10 | 桂林商源植物制品有限公司 | 用于治疗口腔溃疡、肿瘤的中药组合物及其制备方法和用途 |
| CN102724991B (zh) * | 2009-11-26 | 2014-10-29 | 桂林商源植物制品有限公司 | 用于治疗口腔溃疡、肿瘤的中药组合物及其制备方法和用途 |
| CN103373913A (zh) * | 2012-04-15 | 2013-10-30 | 四川省中医药科学院 | 紫草素的提取方法 |
| CN103373913B (zh) * | 2012-04-15 | 2015-08-26 | 四川省中医药科学院 | 紫草素的提取方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1090485C (zh) | 2002-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100335117C (zh) | 新生儿退黄中药洗液 | |
| CN101596230A (zh) | 一种治疗肝病的药物组合物 | |
| CN101195008B (zh) | 一种治疗妇科疾病的黄蒲洁肤洗剂及其制备工艺 | |
| CN102552769A (zh) | 一种治疗阴道炎的药物及其制备方法 | |
| CN101850032B (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
| CN1090485C (zh) | 抗银屑病胶囊及其制备方法 | |
| CN103191167B (zh) | 华泽兰的应用 | |
| CN106543249A (zh) | 一种从虎杖中提取防治高尿酸血症及痛风药用单体的制备方法 | |
| CN101564418B (zh) | 一种治疗口腔溃疡的药物组合物 | |
| CN1259945C (zh) | 小儿柴胡、桂枝退热中药制剂 | |
| CN1104246C (zh) | 一种治疗肛肠疾病的熏洗液及制备方法 | |
| CN101041010A (zh) | 一种治疗消渴(糖尿病)的药物组合物及制备方法 | |
| CN1127344C (zh) | 一种治疗糖尿病及其并发症的口服丸剂 | |
| CN1237998C (zh) | 治疗小儿咳喘的泡腾片 | |
| CN102406790A (zh) | 一种治疗乳腺增生疾病的中药胶囊及其制备方法 | |
| CN116763844B (zh) | 一种用于治疗气道炎症的中药组合物及其制备方法 | |
| CN102885915B (zh) | 解毒止泻缓释胶囊的制备方法 | |
| CN110075176A (zh) | 一种用于治疗腹盆腔疾病术后粘连的中药组合物及其用途 | |
| CN1196256A (zh) | 防治心脑血管病、治疗前列腺增生症的药物及制备方法 | |
| CN1586584A (zh) | 鼻渊胶囊及其制备方法 | |
| CN1839975A (zh) | 一种治疗痔疮的药物及其制备方法 | |
| CN1141113C (zh) | 一种治疗消化性溃疡的中成药 | |
| CN1189207C (zh) | 一种提高人体免疫力的中药组合物及其制备方法 | |
| CN103239522A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN106377651A (zh) | 一种从土茯苓中提取防治高尿酸血症及痛风药用单体的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |